Well it's the way Royalty Pharma (and similar companies) values these royalty interests when they buy them. I suppose there is the argument that the MNTA R&D spend acts to defer taxation for the next few years, but at the end of the day it's (hopefully) only a short-term deferral.
Market Data 
Markets 
AI
